Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Glycaemic Response to High REsistant STarch Bread (REST)

16. februar 2022 oppdatert av: Quadram Institute Bioscience
This study evaluates if the consumption of one sbeIIa/b white bread with high resistant starch content will result in a lower blood glucose response and increased satiety compared with reference white bread. All participants will be asked to consume once the sbeIIa/b white bread and the reference white bread during different visits.

Studieoversikt

Status

Fullført

Detaljert beskrivelse

In an attempt to increase dietary fibre intake, research has focused on developing wheat-based food products with novel fibres and starches to complement fibre intake from whole grain foods. Resistant starch is starch that escapes digestion in the small intestine and may be fermented in the large intestine by the microbiota. Resistant starch is a type of dietary fibre and it is normally found in wheat-based foods made from refined flour but only in small amounts. White bread made from sbeIIa/b wheat, which has high levels of resistant starch (a type of fibre), is showing promise in modulating blood glucose response and increasing satiety compared with conventional white bread.

The primary aim of this study is to determine whether consumption of sbeIIa/b white bread at breakfast, gives rise to a lower postprandial blood glucose response compared with consumption of a reference white bread in healthy individuals.

Additional aims of the study include: determining whether consumption of sbeIIa/b white bread by healthy subjects, gives rise to a lower glucose concentration in interstitial fluid, as measured by a Continuous Glucose Monitoring system (CGM), compared with consumption of control white bread; and exploring satiety and energy intake changes in healthy individuals following consumption of sbeIIa/b white bread at breakfast, compared with consumption of control white bread.

Studietype

Intervensjonell

Registrering (Faktiske)

21

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Norfolk
      • Norwich, Norfolk, Storbritannia, NR4 7UQ
        • Quadram Institute

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Men and women
  • Aged 18 to 65 years
  • BMI between 18-25 kg/m2
  • Non-smokers
  • Those that live within a 40-mile radius of Norwich

Exclusion Criteria:

  • Fasting glucose >6.1 mmol/L and/or HbA1c>42 mmol/mol, as assessed by a fasting blood test
  • Eligibility screening results indicate they are not suitable to take part in this study
  • Smokers (if they have smoked within the 6 weeks prior to the study or during the study)
  • Suffer from allergy, intolerance, or sensitivity to gluten, yeast or any of the food ingredients used in this study
  • Have a known allergy to adhesives that would prevent proper attachment of the Continuous Glucose Monitoring sensors
  • Are pregnant and/or have been pregnant in the last year or are lactating and/or breastfeeding
  • Are currently suffering from, or have ever suffered from eating disorders, any diagnosed gastrointestinal disease, gastrointestinal disorders including regular diarrhoea and constipation (excluding hiatus hernia unless symptomatic) or other inflammatory diseases like rheumatoid arthritis (RA), polymyalgia rheumatica or other connective tissues diseases
  • Have undergone gastrointestinal surgery; this will be assessed on an individual basis
  • Have been diagnosed with diabetes, anaemia as this may affect the study outcome
  • Have been diagnosed with any long-term medical condition that may affect the study outcome (e.g. cardiovascular diseases, cancer)
  • Regularly take over-the-counter medications for digestive/gastrointestinal conditions
  • Use medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including long-term steroids, antibiotics. They may be able to participate if 4 weeks or more have passed from the end of a course such medication
  • Regularly take laxatives (once a month or more) as this may affect blood glucose levels
  • Take certain dietary supplements or herbal remedies and are unwilling to stop taking them (if required) for two weeks prior to and during the study period
  • Are on, or plan to start, a diet programme that may affect the study outcome (e.g. 5:2 fasting diet) unless willing to abstain for 1 month prior to and during the study period
  • Went through a weight change of ≥ 3kg in the preceding 2 months
  • Have a recent history of substance abuse
  • Regularly consume more than 14 units of alcohol a week
  • Are unwilling to suspend smoking and vaping for the duration of the study.
  • Are participating in another research project that involves dietary intervention or blood sampling.
  • Are unwilling to provide GPs contact details
  • Are related to or living with any member of the study team.
  • Are unable to provide written informed consent
  • Have not donated blood or taken part in another dietary intervention in the last 16 weeks and are unwilling to wait until 16 weeks have elapsed
  • Those with abnormal blood pressure measurements

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: sbeIIa/b white bread
sbeIIa/b white bread with high resistant starch content
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
Aktiv komparator: Control white bread
Reference white bread (wild-type)
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in postprandial capillary glucose concentration
Tidsramme: 3.5 hours

Glucose concentration in capillary blood measured by finger prick test after the consumption of sbeIIa/b white bread compared to control white bread.

Measurements will be taken during intervention visit 1 and 2 at -15, -10, -5, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210 min.

3.5 hours

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in postprandial glucose concentration in interstitial fluid
Tidsramme: 4 hours

Glucose concentration in interstitial fluid measured by continuous glucose monitoring system after the consumption of sbeIIa/b white bread compared to control white bread.

Measurements will be taken during intervention visit 1 and 2 between -30 to 210 min.

4 hours
Ad libitum intake
Tidsramme: 2 hours

Mean energy intake (kcal) at lunch after consumption of sbeIIa/b and control white bread.

Measurements will be taken once during intervention visit 1 and 2.

2 hours
Change in postprandial glucose concentration in interstitial fluid
Tidsramme: 4 hours

Glucose concentration in interstitial fluid measured by continuous glucose monitoring system after the consumption of ad libitum lunch to explore any second meal effects caused by prior intake of either sbeIIa/b white bread and control white bread at breakfast.

Measurements will be taken during intervention visit 1 and 2 between 225 to 465 min.

4 hours
Satiety
Tidsramme: 3 hours

Change of hunger feeling (appetite) will be examined using visual analog scale (0-10), 0 least and 10 greatest.

Measurements will be taken during intervention visit 1 and 2, at 0, 32, 92, 182 min.

3 hours
Sensory questionnaire
Tidsramme: 30 minutes

Sensory perception of sbeIIa/b white bread and control white bread will be evaluated using a nine-point hedonic scale to determine any differences overall acceptability based on specific attributes.

A Just-About-Right (JAR) scale with five anchor points will be used to measure the appropriateness of the level of specific attributes to evaluate aroma, appearance, taste and texture of breads.

Measurements will be taken once during intervention visit 1 and 2.

30 minutes

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Marina Corrado, MSc, PhD student

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. januar 2020

Primær fullføring (Faktiske)

30. april 2021

Studiet fullført (Faktiske)

30. april 2021

Datoer for studieregistrering

Først innsendt

9. desember 2019

Først innsendt som oppfylte QC-kriteriene

12. desember 2019

Først lagt ut (Faktiske)

13. desember 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. februar 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. februar 2022

Sist bekreftet

1. februar 2022

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • QIB02/2019

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

Ja

IPD-planbeskrivelse

De-identified individual participant data for primary and secondary outcome measures will be made available

IPD-delingstidsramme

Data will be available after publication in scientific journal within 18 months of study completion

Tilgangskriterier for IPD-deling

Data access will be reviewed by the study team

IPD-deling Støtteinformasjonstype

  • Studieprotokoll
  • Statistisk analyseplan (SAP)
  • Informert samtykkeskjema (ICF)
  • Klinisk studierapport (CSR)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere